StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Delorazepam

HCID 17925
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
2894-67-9
Standard-SMILES
O=C1CN=C(c2ccccc2Cl)c2cc(Cl)ccc2N1
InChIKey
CHIFCDOIPRCHCF-UHFFFAOYSA-N
Summenformel
C15H10Cl2N2O
Durchschnittliche Molmasse
305,2 g/mol
Monoisotopische Masse
304,0170183

Überblick

Delorazepam is a benzodiazepine.

Namen und Bezeichner

Bevorzugter Name
Delorazepam
IUPAC
7-chloro-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
Lokaler Name
Delorazepam
Englischer Name
Delorazepam
Summenformel
C15H10Cl2N2O
Molmasse
305.16

Namen und Synonyme

Delorazepam2894-67-9ChlordemethyldiazepamB1, BenzodiazepineCl-DMDZ2-Chloronordiazepam2'-chloronordiazepamDadumirRo 5-3027RV-121652H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
Weitere Namen anzeigen
EN7-Chloro-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one7-Chloro-5-(2-Chlorophenyl)-1,3-Dihydro-3H-1,4-Dibenzodiazopine-2-OneE5NTL-VAPCALJAL-VAP-2
NSC-169895DTXSID70183137O91W32476G1,3-Dihydro-7-chloro-5-(o-chlorophenyl)-2H-1,4-benzodiazepin-2-onechlorodesmethyldiazepamNSC169895RefChem:5856737-chloro-5-(2-chlorophenyl) 1,3-dihydro-2H-1,4-benzodiazepin-2-one

Datenbank-Bezeichner

CAS
2894-67-9
PubChem CID
17925
DTXSID
DTXSID70183137

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
3,1
Polarare Oberfläche (TPSA)
41,5 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
1
Schwere Atome
20
Formalladung
0
Komplexität
413

Experimentelle und physikochemische Eigenschaften

Drugs · 4 Einträge

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP3.15
Human DrugsPharmaceuticals

Physikochemische Eigenschaften

Schmelzpunkt
187 · 187-189°C
Siedepunkt
481.7 · 481.7±45.0 °C(Predicted)
Dichte
1.42 · 1.42±0.1 g/cm3(Predicted)
Flammpunkt
11 °C · 11 °C
storage temp.
2 · 2-8°C
Löslichkeit
30 mg/ml; · DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml; Ethanol: 10 mg/ml
pka
11.58 · 11.58±0.70(Predicted)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (97.6%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory Information · 2 Einträge

DEA schedule IV controlled substance

REACH registered substance: Delorazepam (EC: 220-771-9)

Hazard Classes and CategoriesAcute Tox. 4 (97.6%)

Toxikologische Informationen

Treatment · 1 Eintrag

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

Chemie und Industrie

Pharmakologische Informationen

Protein Binding>90% protein bound.
Biological Half-LifeVery long elimination half life of 80-115 hours, varying with age. Elimination is slower as age increases. [1] Liver disease also impacts elimination half life, with impairment resulting in half lives up to 395 hours.
Metabolism/Metabolites · 2 Einträge

Delorazepam is metabolized at a relatively slow pace by the liver. The major metabolite (15-34% of the parent drug) is lorazepam. Older patients metabolize delorazepam slower than younger patients.

Delorazepam is metabolized at a relatively slow pace by the liver. The major metabolite (15-34% of the parent drug) is lorazepam. Older patients metabolize delorazepam slower than younger patients.

MeSH Pharmacological ClassificationDrugs used to prevent SEIZURES or reduce their severity.
Absorption, Distribution and Excretion · 4 Einträge

77-87% oral bioavailability, with a relatively slow absorption rate. Reaches peak plasma levels within 1-2 hours of administration. Food may slow absorption, however other pharmacokinetic variables remain unchanged. After multiple doses delorazepam accumulates, although accumulation is slower in younger patients.

Renally eliminated.

140 L/kg apparent volume of distribution in 11 patients with normal renal function; 47 L/kg in 11 patients with renal failure and on regular hemodialysis. In another study, apparent volume of distribution was 65 L/kg in 8 patients with liver disease and 118.4 L/kg in 12 healthy controls.

Still detectable 72 hours after dosing in healthy patients. Patients with liver disease experienced a reduction in clearance from 0.13 to 0.25 ng/mLh.

Verwendung und Herstellung

Uses · 1 Eintrag

Mainly used as an anti-anxiety agent. Studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants; however, after 4 weeks, antidepressants showed superior anti-anxiety effects. Anti-anxiety effects also appear to be weaker in elderly patients. Effectiveness has also been observed in the treatment of alcohol withdrawal. Delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal.

Zugehörige Reaktionen

9
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 649264
HRID 649264als Edukt
Reaktionsgleichung von HRID 649266
HRID 649266als Edukt
Reaktionsgleichung von HRID 673356
HRID 673356als Edukt
Reaktionsgleichung von HRID 805703
HRID 805703als Edukt
Reaktionsgleichung von HRID 1076389
HRID 1076389als Edukt
Reaktionsgleichung von HRID 1138462
HRID 1138462als Edukt
Reaktionsgleichung von HRID 1148992
HRID 1148992als Edukt
Reaktionsgleichung von HRID 1156237
HRID 1156237als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEMBL
CHEMBL268254
ChEBI
CHEBI:135295
UNII
O91W32476G
EC Number
220-771-9
Nikkaji
J7.928F
Aggregatzustand
buffered aqueous solution
Biologische Quelle
mouse
InChIKey
CHIFCDOIPRCHCF-UHFFFAOYSA-N
CAS Datenbank
2894 · 2894-67-9(CAS DataBase Reference)
NIST chemische Informationen
Delorazepam(2894-67-9)
Exposure Routes · 1 Eintrag

77-87% oral bioavailability, with a relatively slow absorption rate. Reaches peak plasma levels within 1-2 hours of administration. Food may slow absorption, however other pharmacokinetic variables remain unchanged. After multiple doses delorazepam accumulates, however accumulation is slower in younger patients.

Toxicity Summary · 1 Eintrag

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Signs and SymptomsOlder patients metabolize delorazepam slower than younger patients and thus suffer from more adverse effects.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Sicherheitsdaten

wgk
3
ridadr
UN 1230 3/PG 2
RTECS-Nr.
DF2367500
risk_code
22-39/23/24/25-23/24/25-11
Toxizität
LD50 oral in rat: 2gm/kg
hazard_code
Xn,T,F
safety_code
36/37/39-45-36/37-16-7
Speicherklasse
10 - Combustible liquids
Use ClassificationPharmaceuticals

Anwendungen

VerwendenControlled Substance